Home›Stock Screener›Venus Remedies

Venus Remedies Share Price Today | Stock Price & Venus Remedies Share Screener

VENUSREM Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1501.60
▲ 46.60 (3.20%)
2026-11-19 00:00:00
Live Share Price BSE
₹1500.75
▲ 51.45 (3.55%)
2026-11-19 00:00:00

As of November 19, 2026, the live Venus Remedies share price (NSE: VENUSREM) is ₹1,501.60 on NSE and ₹1,500.75 on BSE, up 3.20% from the previous close, with shares trading between ₹1,431.00 and ₹1,527.70 in today's trading session, and a 52-week range of ₹651.45–₹1,796.10. Track Venus Remedies networth to gauge the company's total market size. Use the Venus Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Venus Remedies opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹264 and net income of ₹48, with EBITDA of ₹68, an operating margin of 24.0% and a profit margin of 18.2%.

Venus Remedies Market Cap ₹2,074.96 Cr.
VENUSREM P/E Ratio (TTM) 16.50
Venus Remedies P/B Ratio 2.85
EPS (TTM) ₹76.90
Dividend Yield 0.67%
Debt to Equity 0.01
VENUSREM 52 Week High ₹1796.10
Venus Remedies 52 Week Low ₹651.45
Operating Margin 24.00%
Profit Margin 18.18%
VENUSREM Revenue (TTM) ₹264.00
EBITDA ₹68.00
Net Income ₹48.00
Total Assets ₹854.00
Total Equity ₹664.00

Venus Remedies Share Price Chart

Track the current stock price of Venus Remedies with an interactive chart. Analyse VENUSREM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Venus Remedies stock quote in one place.

The quote of ₹1,501.60 sits between the 52-week low of ₹651.45 and the 52-week high of ₹1,796.10, and the latest session moved 3.20% from the previous close.

Venus Remedies Company Profile - Fundamental Screener

Screen Venus Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VENUSREM shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE411B01019.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE411B01019

Venus Remedies Balance Sheet Screener

Screen VENUSREM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹854, up from ₹716 in 2025.

Latest statistics put total assets at ₹854 and shareholder funds at ₹664, with a leverage ratio of 0.01.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 854 716 627 601 580 556 644 733 751 765
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 232 229 219 216 241 262 289 364 389 406

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 28 19 60 58 47 58 96 137 159 180
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 664 561 488 460 440 400 323 333 362 389
Share Capital 13 13 13 13 13 12 12 12 12 12
Reserves & Surplus 650 548 474 447 427 374 311 320 350 376

Venus Remedies Income Statement Screener - Profit & Revenue Analysis

Screen Venus Remedies income statement and profit fundamentals. Analyze VENUSREM quarterly results. Venus Remedies reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹264 and net profit was ₹48, equal to earnings per unit of ₹35.53, at an operating margin of 24%.

In that period expenses were ₹196, interest cost ₹0 and tax ₹14. The next period listed, 2026-Jun, shows revenue of ₹182 and net profit of ₹23.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 264 182 219 202 141 195 183 199 110 178 189 159 97 171 146
Expenses 196 145 176 166 122 162 143 176 97 163 159 131 85 150 131

Operating Costs and Margins

EBITDA 68 37 43 36 19 33 40 23 13 16 30 28 13 21 14
Operating Profit % 24.00% 19.00% 19.00% 15.00% 11.00% 16.00% 21.00% 10.00% 10.00% 4.00% 10.00% 16.00% 11.00% 11.00% 8.00%
Depreciation 7 7 10 5 6 6 7 6 6 6 5 8 8 6 7
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 62 30 34 31 13 27 34 18 7 9 25 20 5 14 8
Tax 14 7 8 10 3 6 8 7 6 6 5 9 4 4 1
Net Profit 48 23 26 21 10 20 26 11 1 4 20 11 1 10 7
EPS 35.53 17.18 19.19 15.71 7.18 15.06 19.14 7.86 0.92 2.63 14.66 8.27 0.88 7.44 5.13

Venus Remedies Cash Flow Screener - Liquidity Fundamentals

Screen VENUSREM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹156, and net cash flow was an outflow of ₹32.

Over the same period, investing activities used ₹185 and financing activities used ₹3.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 156 86 37 37 41 132 78 45 31 59
Investing Activities -185 -77 -9 -58 -17 57 -5 -11 9 -18

Financing and Net Cash

Financing Activities -3 -1 -1 -1 -10 -162 -73 -35 -39 -44
Net Cash Flow -32 9 28 -22 14 27 0 -1 0 -4

Venus Remedies Shareholding Pattern Screener

See Venus Remedies shareholding pattern with promoter, FII, and DII holdings. Check Venus Remedies promoter holding and ownership changes for VENUSREM on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 41.76%, foreign institutions 2.80%, domestic institutions 1.20% and the public 44.39%, spread across 18,403 shareholders.

The shareholder count was 18,403 in 2026-Mar, compared with 21,905 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76%

Institutional Investors

FII Holding 2.80% 2.92% 3.14% 1.34% 2.24% 1.86% 2.26% 1.48%
DII Holding 1.20% 0.89% 0.74% 0.00% 0.11% 0.75% 1.03% 0.15%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 44.39% 44.31% 44.01% 46.81% 47.70% 45.30% 45.16% 46.89%
Other Holding 9.85% 10.12% 10.35% 10.09% 8.19% 10.33% 9.80% 9.73%
Shareholder Count 18,403 21,905 22,968 19,982 19,307 17,725 18,606 19,913

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Venus Remedies. Venus Remedies dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹10.00 per unit for 2026-March, a yield of 0.67%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹10.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹10.00 0.67%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Venus Remedies Stock Index Membership - Nifty & Sensex

See which indices include Venus Remedies stock. Check VENUSREM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Venus Remedies is not part of any tracked indices.
Only major market indices are tracked in our system.

Venus Remedies Market Events Screener - Corporate Actions

Get Venus Remedies corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Venus Remedies stock events that may affect VENUSREM share price, along with derivatives, futures and options activity and sector gainers.

13 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 26, 2026, with a record date of October 26, 2026.

It is followed by Annual General Meeting dated August 20, 2026 and Dividend dated August 7, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-26 2026-10-26 Quarterly Result Announcement NA -11.84%
2026-08-20 2026-08-20 Annual General Meeting NA 56.05%
2026-08-07 2026-08-07 Dividend ₹ 10.00 /share 37.52%
2026-07-20 2026-07-20 Quarterly Result Announcement NA 6.02%
2026-05-26 2026-05-26 Quarterly Result Announcement NA 20.91%
2026-01-29 2026-01-29 Quarterly Result Announcement NA -3.15%
2025-11-10 2025-11-10 Quarterly Result Announcement NA 1.78%
2025-08-22 2025-08-22 Annual General Meeting NA 14.50%
2025-08-01 2025-08-01 Quarterly Result Announcement NA -2.92%
2025-05-26 2025-05-26 Quarterly Result Announcement NA 3.36%
2025-02-04 2025-02-04 Quarterly Result Announcement NA -1.96%
2024-10-29 2024-10-29 Quarterly Result Announcement NA -0.66%
2024-09-23 2024-09-23 Annual General Meeting NA 0.93%

Venus Remedies Competitors Screener - Peer Stocks Comparison

Screen VENUSREM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 453,234 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 300,710 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 179,245 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 127,265 98.10 6,868 22.01% 890 69.60
Zydus Life Science 119,700 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 116,213 41.70 35,059 3.90% 4,158 70.24
Cipla 113,294 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 110,105 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 105,829 26.40 34,145 5.56% 3,503 66.06
Lupin 91,623 17.30 29,039 26.75% 5,356 44.92

Venus Remedies Company Announcements - News & Reports Screener

Screen VENUSREM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 10, 2026.

The next most recent announcements are dated November 4, 2026 and October 28, 2026.

Date Update Actions
2026-11-10 Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited -
2026-11-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-28 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-26 Unaudited Financial Results For The Period Ended On 30Th September 2026. -
2026-10-26 Board Meeting Outcome for Outcome Of Board Meeting Date 26Th October 2026 And Unaudited Financial Results For The Period Ended On 30Th September 2026. -
2026-10-16 Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets -
2026-10-14 Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests -
2026-10-14 Board Meeting Intimation for Notice Of Board Meeting Dated 26Th October 2026. -
2026-10-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-30 Intimation For Change In Company Identification Number (CIN). -
2026-09-25 Closure of Trading Window -
2026-09-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-08 Social Media Post On Shareholders Awareness On Transfer Of Physical Shares. -
2026-08-21 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-21 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -
2026-08-21 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-20 Announcement under Regulation 30 (LODR)-Change in Management -
2026-08-20 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,501.60, within a 52-week range of ₹651.45 to ₹1,796.10. The P/E ratio is 16.50 and the P/B ratio is 2.85, with earnings per unit of ₹76.90. Market capitalisation stands at ₹2,074.96 Cr and the dividend yield is 0.67%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.